Therapeutical Targets in Allergic Inflammation

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Nov 11

PMID 36359393

Authors

Lorenzo Salvati

Francesco Liotta

Francesco Annunziato

Lorenzo Cosmi

Affiliations

Soon will be listed here.

Abstract

From the discovery of IgE to the in-depth characterization of Th2 cells and ILC2, allergic inflammation has been extensively addressed to find potential therapeutical targets. To date, omalizumab, an anti-IgE monoclonal antibody, and dupilumab, an anti-IL-4 receptor α monoclonal antibody, represent two pillars of biologic therapy of allergic inflammation. Their increasing indications and long-term follow-up studies are shaping the many different faces of allergy. At the same time, their limitations are showing the intricate pathogenesis of allergic diseases.

Citing Articles

High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis.

Wang A, Zhou Y, Luo Y, Gao Y, Chen J, Li W Front Immunol. 2023; 14:1160710.

PMID: 37153599 PMC: 10157040. DOI: 10.3389/fimmu.2023.1160710.

CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease.

Gomez-Bris R, Saez A, Herrero-Fernandez B, Rius C, Sanchez-Martinez H, Gonzalez-Granado J Int J Mol Sci. 2023; 24(3).

PMID: 36769019 PMC: 9916759. DOI: 10.3390/ijms24032696.

Editorial: Pathophysiological and clinical advances in asthmatic inflammation from the nasopharynx to the peripheral airway in the respiratory tract systems.

Koga Y, Kamide Y, Hisada T, Ishizuka T Front Pharmacol. 2023; 14:1037610.

PMID: 36726579 PMC: 9885187. DOI: 10.3389/fphar.2023.1037610.

References

Serrano-Candelas E, Martinez-Aranguren R, Valero A, Bartra J, Gastaminza G, Goikoetxea M . Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2015; 46(1):92-102. DOI: 10.1111/cea.12668. View

Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P . Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014; 133(6):1709-19.e8. PMC: 4083100. DOI: 10.1016/j.jaci.2014.02.005. View

Agache I, Rocha C, Beltran J, Song Y, Posso M, Sola I . Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75(5):1043-1057. DOI: 10.1111/all.14235. View

Hirano T, Koyanagi A, Kotoshiba K, Shinkai Y, Kasai M, Ando T . The Fab fragment of anti-IgE Cε2 domain prevents allergic reactions through interacting with IgE-FcεRIα complex on rat mast cells. Sci Rep. 2018; 8(1):14237. PMC: 6155129. DOI: 10.1038/s41598-018-32200-z. View

Greuter T, Hirano I, Dellon E . Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol. 2019; 145(1):38-45. PMC: 6981295. DOI: 10.1016/j.jaci.2019.10.027. View

Zhao Z, Ji C, Yu W, Meng L, Hawro T, Wei J . Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016; 137(6):1742-1750.e4. DOI: 10.1016/j.jaci.2015.12.1342. View

Tonacci A, Nettis E, Asero R, Rossi O, Tontini C, Gangemi S . Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence. Eur Ann Allergy Clin Immunol. 2020; 52(3):100-103. DOI: 10.23822/EurAnnACI.1764-1489.136. View

Gevaert P, Omachi T, Corren J, Mullol J, Han J, Lee S . Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020; 146(3):595-605. DOI: 10.1016/j.jaci.2020.05.032. View

Oude Elberink H, Jalving M, Dijkstra H, van de Ven A . Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study. Clin Transl Allergy. 2020; 10:5. PMC: 6990484. DOI: 10.1186/s13601-020-0309-0. View

10.

Holgate S, Chuchalin A, Hebert J, Lotvall J, Persson G, Chung K . Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004; 34(4):632-8. DOI: 10.1111/j.1365-2222.2004.1916.x. View

11.

Sutton B, Davies A . Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol Rev. 2015; 268(1):222-35. DOI: 10.1111/imr.12340. View

12.

Eger K, Pet L, Weersink E, Bel E . Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021; 9(7):2913-2915. DOI: 10.1016/j.jaip.2021.02.042. View

13.

Cosmi L, Maggi L, Mazzoni A, Liotta F, Annunziato F . Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis. Eur J Immunol. 2019; 49(9):1334-1343. DOI: 10.1002/eji.201948156. View

14.

Gemici Karaaslan H, Yilmaz E, Gulmez R, Canpolat N, Kiykim A, Cokugras H . Omalizumab may facilitate drug desensitization in patients failing standard protocols. Pediatr Allergy Immunol. 2022; 33(5):e13783. DOI: 10.1111/pai.13783. View

15.

Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G . Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014; 7:123-30. PMC: 4159398. DOI: 10.2147/JAA.S52387. View

16.

Hanania N, Alpan O, Hamilos D, Condemi J, Reyes-Rivera I, Zhu J . Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011; 154(9):573-82. DOI: 10.7326/0003-4819-154-9-201105030-00002. View

17.

Bardelas J, Figliomeni M, Kianifard F, Meng X . A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012; 49(2):144-52. DOI: 10.3109/02770903.2011.648296. View

18.

Weiss S, Smith D . A Case of Serum Sickness-Like Reaction in an Adult Treated with Omalizumab. Mil Med. 2019; 185(5-6):e912-e913. DOI: 10.1093/milmed/usz357. View

19.

Bumbacea R, Ali S, Corcea S, Spiru L, Nitipir C, Strambu V . Omalizumab for successful chemotherapy desensitisation: What we know so far. Clin Transl Allergy. 2021; 11(10):e12086. PMC: 8667670. DOI: 10.1002/clt2.12086. View

20.

MacGinnitie A, Rachid R, Gragg H, Little S, Lakin P, Cianferoni A . Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2016; 139(3):873-881.e8. PMC: 5369605. DOI: 10.1016/j.jaci.2016.08.010. View